Table 4. Multivariate Cox proportional hazards model analysis for TTF and OS in patients with wild-type non-small cell lung cancer treated with ICIs.
| TTF | OS | ||||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | ||
| Age (<70 vs. ≥70 years) | 0.61 | 0.27–1.36 | 0.23 | 0.98 | 0.37–2.55 | 0.96 | |
| Sex (female vs. male) | 2.40 | 0.87–6.61 | 0.08 | 4.99 | 1.30–19.0 | 0.01 | |
| Smoking† (no vs. yes) | 0.43 | 0.14–1.28 | 0.13 | 0.43 | 0.11–1.67 | 0.22 | |
| Histology (non-sq vs. sq) | 0.98 | 0.46–2.09 | 0.96 | 0.43 | 0.16–1.16 | 0.09 | |
| ECOG PS (0–1 vs. ≥2) | 1.43 | 0.64–3.16 | 0.37 | 2.93 | 1.13–7.56 | 0.02 | |
| NLR (<5 vs. ≥5) | 5.06 | 2.08–12.3 | <0.01 | 2.48 | 1.02–5.98 | 0.04 | |
| 1st line cytotoxic anticancer drugs (platinum-based doublet vs. monochemotherapy) | 0.95 | 0.45–1.98 | 0.89 | 2.12 | 0.91–4.96 | 0.08 | |
| Best response to previous therapy before ICI (non-PD vs. PD) | 3.77 | 1.66–8.55 | <0.01 | 6.29 | 2.41–16.40 | <0.01 | |
| PD-L1 expression (positive vs. negative) | 1.77 | 0.85–3.67 | 0.12 | 2.72 | 1.17–6.31 | 0.01 | |
| ICI treatment line (2nd/3rd vs. later) | 1.16 | 0.39–3.41 | 0.78 | 0.30 | 0.07–1.16 | 0.09 | |
†, history of >10 pack years. TTF, time to treatment failure; OS, overall survival; HR, hazard ratio; CI, confidence interval; sq, squamous; ECOG PS, Eastern Cooperative Group performance status; NLR, neutrophil-to-lymphocyte ratio; ICI, immune checkpoint inhibitor.